By admin 
The 2025 data, released in mid-2026, reveals that the percentage of young adults who reported using nicotine vapes in the past 30 days has reached its highest level since the University of Michigan first began tracking the specific metric in 2017. Over that short nine-year span, the prevalence of nicotine vaping has more than tripled, climbing to a record 19%. This surge reflects not only the technological refinement of e-cigarettes—which have become more discreet, flavorful, and potent—but also a shifting social acceptance that has decoupled nicotine use from the stigma of smoking.
Parallel to the rise in vaping is the continued normalization of cannabis. According to the survey, 29% of young adults between the ages of 19 and 30 reported using cannabis in the past 30 days. While this is a marginal decrease from the previous year’s all-time high of 30%, the more concerning metric for public health officials is the frequency of use. A record-breaking 12% of young adults now report daily or near-daily cannabis use, defined as using the drug 20 or more times in the past month. This suggests that for a significant portion of the population, cannabis has moved from a recreational weekend activity to a daily habit, potentially raising risks for dependency and long-term cognitive impacts.
The Monitoring the Future survey is a cornerstone of American epidemiological research. Supported by the National Institutes of Health (NIH) and managed by the National Institute on Drug Abuse (NIDA), the study gathers data from approximately 20,000 individuals annually, spanning ages 19 to 65. By tracking the same cohorts over decades, researchers can distinguish between age-related changes and broader generational shifts. Dr. Nora Volkow, the director of NIDA, characterized this year’s findings as a "mixed picture" that demands nuanced intervention strategies.
"It is reassuring to continue to see relatively low smoking rates and a continuing decline in alcohol use among adults," Dr. Volkow stated in a press release accompanying the report. "At the same time, rising rates of cannabis, nicotine, and certain other drug use warrant attention. Continued monitoring is vital for understanding the changing drug landscape so that we can develop effective interventions to support public health."
The decline of alcohol, while slow, remains a notable trend in the data. Alcohol remains the most widely consumed substance across all adult age groups, with roughly 60% of young adults (19-30) and middle-aged adults (35-50) reporting consumption in the past 30 days. However, the intensity and frequency of drinking have seen a downward trajectory. This shift is often attributed to the "sober curious" movement and a growing awareness among Gen Z and Millennials regarding the long-term health risks of ethanol, including its links to cancer and liver disease.
Similarly, the traditional combustible cigarette is becoming a relic for younger Americans. Only 8% of young adults reported smoking a cigarette in the past 30 days, a figure that has been in steady decline since 2004. However, researchers noted a potential "plateauing" of this decline. The concern among experts is that the remaining 8% may represent a "hardcore" group of smokers for whom standard cessation messaging is less effective, or perhaps a group that dual-uses both cigarettes and vapes.
While cigarettes fade, the nicotine market is diversifying. The MTF survey began tracking nicotine pouches, such as the brand Zyn, in 2023. In just two years, the reported use of these pouches among young adults in the past 12 months has more than doubled, jumping from 5% to 13%. These small, tobacco-free sachets are placed under the lip and deliver a concentrated dose of nicotine without the need for inhalation. Their rise has been fueled by viral social media trends and the industry’s marketing of them as a "cleaner" alternative to both smoking and vaping.
The rapid adoption of nicotine pouches has sparked a fierce debate among regulators and health advocates. Tim McAfee, the former head of the Office of Smoking and Health at the Centers for Disease Control and Prevention (CDC), expressed deep concern over the regulatory environment. He pointed specifically to the Food and Drug Administration’s (FDA) recent decisions, including the authorization of new flavored nicotine pouches and the June decision to allow Zyn to be marketed with "modified risk" claims, suggesting they are less harmful than cigarettes.
"Tobacco companies use FDA harm reduction claims to help them in their marketing not just to current cigarette smokers, but to help open new markets appealing to people not currently smoking," McAfee said via email. He argued that the industry’s "harm reduction" narrative is often a Trojan horse designed to hook a new generation on nicotine, regardless of the delivery method.
The political climate has further complicated the vaping landscape. The survey’s findings on e-cigarettes come in the wake of controversial moves by the Trump administration. In the spring of 2026, the FDA authorized fruit-flavored vapes for the first time in years, provided they utilized "age-gated" technology—biometric or digital locks intended to prevent use by those under 21. Critics, however, remain skeptical of the efficacy of these safeguards. Shortly after this authorization, the agency announced a policy of non-prioritization for enforcement against certain unauthorized fruit-flavored vapes already on the market, a move that public health advocates say essentially opens the floodgates for products that appeal directly to youth.
Stefanie Gratale, an assistant professor at the Rutgers School of Public Health who specializes in tobacco control, noted that while e-cigarettes may offer a "bridge" for older smokers looking to quit, they represent a "trap" for young non-smokers. "It’s difficult to pinpoint one cause for observed trends, but access to unauthorized flavored e-cigarette products, difficulty in enforcing regulations, and competing priorities in siloed regulatory approaches at state and federal levels can all play a role," Gratale said. She emphasized the need for a unified policy that communicates the "spectrum of risks" across different products without inadvertently encouraging the initiation of nicotine use among the youth.
Beyond nicotine and cannabis, the 2025 survey highlighted a few unexpected fluctuations in other drug categories. Heroin use among young adults saw a slight but statistically significant uptick, rising from 0.2% in 2024 to 0.6% in 2025. While the absolute numbers remain low, any increase in heroin use is viewed with alarm given the ongoing fentanyl crisis, where illicit drug supplies are frequently contaminated with lethal synthetic opioids. Conversely, the use of psychedelics—which had been on a steady rise due to the "psychedelic renaissance" in mental health treatment—saw a dip from 9% to 7%. This may suggest a cooling of the trend or a shift toward more controlled, therapeutic environments rather than recreational use.
The commercial determinants of health—a term referring to the private sector activities that affect people’s health—are central to these findings. The survey suggests that the decline in cigarette use is being offset by the aggressive marketing of newer, high-tech nicotine and THC delivery systems. As Tim McAfee noted, while cigarette use is at a historic low, "hundreds of thousands of Americans are still dying from smoking-related diseases." The emergence of new products ensures that the cycle of addiction continues, albeit in different packaging.
As the University of Michigan and the NIH continue to digest these results, the data serves as a critical call to action for policymakers. The record highs in vaping and daily cannabis use among young adults indicate that current prevention and education strategies may be lagging behind the rapid innovation of the drug industry. For public health officials, the challenge is twofold: maintaining the downward trend of traditional smoking and drinking while simultaneously curbing the explosive growth of the new, digitalized landscape of substance use. The MTF survey remains the most vital tool for navigating this "changing drug landscape," providing the evidence base needed to protect the health of the next generation.
